Stanley Laman Group, Ltd. Aldeyra Therapeutics, Inc. Transaction History

Stanley Laman Group, Ltd.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Oct 30, 2018	SELL	$6.8 - $14.35 $672,465 - $1.42 Million	-98,892 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$6.95 - $9.18 $242,297 - $320,042	34,863 Added 54.45%	98,892 $786,000
Q1 2018 May 01, 2018	BUY	$6.55 - $8.9 $419,389 - $569,858	64,029 New	64,029 $480,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $280M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Stanley Laman Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Stanley Laman Group, Ltd. with notifications on news.